Literature DB >> 8482460

Circulating levels of endothelin in cirrhosis.

M Asbert1, A Ginès, P Ginès, W Jiménez, J Clària, J Saló, V Arroyo, F Rivera, J Rodés.   

Abstract

BACKGROUND: Current information concerning endothelin in cirrhosis is conflicting. Plasma endothelin concentration has been found to be increased in some studies and normal or reduced in others. The present study was aimed to investigate the plasma levels of endothelin in cirrhosis and to assess whether it is involved in the renal and hemodynamic disturbances and neurohumoral changes present in this condition.
METHODS: Renal function, plasma renin activity, and plasma concentration of aldosterone, norepinephrine, antidiuretic hormone, atrial natriuretic factor, and endothelin were measured in 9 healthy subjects, 7 compensated cirrhotics, and 25 cirrhotics with ascites (10 with functional renal failure).
RESULTS: Cirrhotics with ascites with and without functional renal failure showed higher endothelin levels (15.6 +/- 6.4 and 15.7 +/- 4.6 pg/mL, respectively; mean +/- SD) than compensated cirrhotics (6.4 +/- 1.8 pg/mL) and healthy subjects (3.4 +/- 1.0 pg/mL) (analysis of variance, F = 21.84; P < 0.001). These patients also showed higher plasma levels of renin, aldosterone, norepinephrine, antidiuretic hormone, and atrial natriuretic factor, although plasma endothelin levels only correlated significantly with plasma atrial natriuretic factor (r = 0.73, P < 0.001) and antidiuretic hormone concentrations (r = 0.59, P < 0.001). In 7 additional nonazotemic cirrhotics with ascites, plasma renin activity and the plasma concentration of aldosterone and endothelin were measured before and 24 hours after the intravenous administration of a saline solution of human serum albumin. Volume expansion markedly suppressed renin and aldosterone but not endothelin (21.03 +/- 7.34 vs. 23.97 +/- 14.29 pg/mL).
CONCLUSIONS: Circulating plasma levels of endothelin are elevated in cirrhosis with ascites and do not decrease following plasma volume expansion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482460     DOI: 10.1016/0016-5085(93)90360-o

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

Review 2.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 3.  Hepatopulmonary syndrome.

Authors:  M B Fallon; G A Abrams
Journal:  Curr Gastroenterol Rep       Date:  2000-02

4.  Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.

Authors:  Ma Somsouk; Rachel Kornfield; Eric Vittinghoff; John M Inadomi; Scott W Biggins
Journal:  Liver Transpl       Date:  2011-02       Impact factor: 5.799

5.  A fascinating presentation of hepatic hydrothorax.

Authors:  Vinaya Gaduputi; Hassan Tariq; Kalyan Kanneganti
Journal:  World J Hepatol       Date:  2013-10-27

6.  Gastric mucosal resistance to acute injury in experimental portal hypertension.

Authors:  S Calatayud; M C Ramírez; M J Sanz; L Moreno; C Hernández; J Bosch; J M Piqué; J V Esplugues
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

7.  Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation.

Authors:  R B Vaughan; P W Angus; J P F Chin-Dusting
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

8.  Protective effects of endothelin-1 on acute pancreatitis in rats.

Authors:  M Kogire; K Inoue; S Higashide; K Takaori; Y Echigo; Y J Gu; S Sumi; K Uchida; M Imamura
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

9.  Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease.

Authors:  M Somsouk; J Guy; S W Biggins; E Vittinghoff; M A Kohn; J M Inadomi
Journal:  Aliment Pharmacol Ther       Date:  2009-07-13       Impact factor: 8.171

Review 10.  Advances in liver transplantation allocation systems.

Authors:  Michael L Schilsky; Maryam Moini
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.